Corcept Therapeutics is the lead sponsor of 9 current clinical trials in our USA, UK, Ireland and India registers. 4 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Miricorilant, Nab-paclitaxel /m^2 and Relacorilant. The most-studied condition is Nonalcoholic Steatohepatitis (NASH).
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317 · ClinicalTrials.gov ↗ · Adenocarcinoma, Carcinoma, Pancreatic Ductal
|
Phase 2 | Recruiting | 2026-01 | USA |
|
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
NCT07276373 · ClinicalTrials.gov ↗ · Neoplasms
Drug: Nivolumab |
Phase 1/2 | Recruiting | 2026-01 | USA |
|
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663 · ClinicalTrials.gov ↗ · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Drug: Miricorilant |
Phase 1 | Recruiting | 2026-04 | USA |
|
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
|
Phase 2 | Recruiting | 2025-04 | USA |
|
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis
|
Phase 2 | Active, closed | 2022-11 | Ireland, UK, USA |
|
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408 · Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Drugs: Nab-paclitaxel /m^2, Relacorilant |
Phase 3 | Active, closed | 2022-06 | UK, USA |
|
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219 · ClinicalTrials.gov ↗ · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Drug: Miricorilant |
Phase 2 | Active, closed | 2023-10 | USA, India |
|
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198 · ClinicalTrials.gov ↗ · Cushing Syndrome
|
Phase 2 | Active, closed | 2018-05 | USA |
|
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
NCT06947304 · ClinicalTrials.gov ↗ · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Drug: Miricorilant |
Phase 1 | Active, closed | 2025-08 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 9 | 4 |
| Clinical trials in UK | 2 | 0 |
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Changchun Intellicrown Pharmaceutical | 1 |
Sponsors with the most current trials registered for this condition.
Corcept Therapeutics is the lead sponsor of 9 current trials on ClinicalTrials.gov in our USA, UK, Ireland and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 5 drugs and biologicals as interventions. The most frequent are Miricorilant (3), Nab-paclitaxel /m^2 (2), Relacorilant (2), Bevacizumab (1) and Nivolumab (1). The number in brackets is how many of its trials name each drug.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.